Medco Health Solutions and Laboratory Corporation of America® agreed to work together to understand the pharmacogenomics behind tamoxifen. This therapy works by depriving certain tumors of estrogen to treat some forms of breast cancer and to prevent recurrence.
Genotyping for the study will be performed using the FDA-cleared Roche AmpliChip® CYP450 test.
Last year, an FDA panel recommended that the tamoxifen label should include a warning that the drug may not work as well to prevent recurrence in postmenopausal women who carry a genetic variant of CYP2D6 of the cytochrome P450 gene family. In fact, approximately 10% of women using tamoxifen do not fully benefit from the drug because of variations in genes encoding drug metabolizing enzymes, according to the collaborators.